‘Legacy’ Drugs And Former US FDA Commissioner Gottlieb’s Legacy

 
• By Michael McCaughan

A surprise move to unwind FDA’s efforts to end the marketing of unapproved drugs is in keeping with the overall sense of the top-down intervention in the agency’s policies at the end of the Trump Administration. It is also an unfortunate consequence of the embrace of drug pricing as part of FDA’s mission.

FDA Commissioner-designate Scott Gottlieb testifies during a Senate Health, Education, Labor and Pensions Committee hearing on April 5, 2017 at on Capitol Hill in Washington, D.C. (Photo by Zach Gibson/Getty Images)
Scott Gottlieb's confirmation hearing seems a long time ago, but his legacy continues at the US FDA. • Source: Photo illustration from picture by Zach Gibson/Getty Images

More from Pricing Debate

More from Market Access